Optimistic Buy Rating for Liquidia Technologies Driven by Promising Developments and Pipeline Expansion
I'm PortAI, I can summarize articles.
Serge Belanger has given Liquidia Technologies an optimistic Buy rating due to promising developments, including a recent R&D event showcasing technologies for respiratory and vascular diseases. Key highlights include Yutrepia, which offers improved tolerability and higher dosing for better patient outcomes, and the upcoming Phase 3 trial for the L606 program, a liposomal formulation of treprostinil. These advancements, along with expected sales growth and a pending patent litigation decision, support the positive outlook. H.C. Wainwright also reiterated a Buy rating with a $35.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments